Haplogen, founded 2010 is a Vienna based, privately owned biotechnology company. Based on a novel mechanism Haplogen develops proprietary small molecule therapeutic compounds for the treatment of diseases that lead to adipositas and obesity.
HeartBeat.bio is an early-stage drug discovery company focused on the development of a high-throughput fully human 3D screening platform for heart diseases. The technology has the potential to radically change the current cardiovascular drug discovery paradigm, leading to higher success rates in clinical trials, reduced cost and time for compound development. HeartBeat.bio’s business strategy is to leverage its screening technology into multiple R
Holloid invented and commercializes a key enabling technology for bioprocess monitoring. This unlocks breakthroughs in biotech and a global transition to more sustainable value chains across industries. Holloid does this by providing 3D-microscopy at scale: fully automated, a thousand times faster, and at a throughput 1 million times higher than comparable existing technologies. We generate and process unique sets of big data on microscopic objects and analyze them with artificial intelligence.
Hypericum LifeScience GmbH (HLS, www.hypericum-ls.com) is an Austrian Start up, founded in 2020 with the focus to develop a new treatment strategy for Glioma Grade III and IV (glioblastoma multiforme). HLS technology is based on a water soluble tumour fluorescent and light active dye (HHL-PVP) to enable Fluorescent Guided Surgery (FGS) in combination with Photo-Dynamic Therapy (PDT) which is subsequently applied to kill remaining tumour cells which were not been able to remove.
JLP Health GmbH, founded by Prof. Josef Penninger and colleagues, employs cutting edge functional genomic technologies that enable the development of rational drugs to combat viral infections and other diseases with high unmet medical need, such as cancer and other life-threatening diseases. JLP's R&D activities are based in Vienna and supported by its subsidiary Acus in Cologne. The Joint Venture Angal Biotechnology enables the international scale-up and opens the Chinese market.
We are an Office GMP Manufacturer that takes care of young and innovative Biotech Startups, to become independent and successful Health Care companies. Our main objective is to empower our clients to keep their investors satisfied and maintain their independence, by entering markets faster with their products. To achieve early market readiness, we provide our GMP-QMS platform, our expertise in product release and guideline-compliant software systems for effective document- and data management.